Retinal Cell Death Therapies

EYVIVA is advancing a highly potent anti-Fas Ligand monoclonal antibody aimed at blocking apoptosis, which is a central upstream driver of retinal cell death and inflammation, particularly in conditions such as Age Related Macular Degeneration and Glaucoma. By targeting a unifying apoptotic pathway that is implicated in multiple retinal diseases, our therapeutic approach holds promise for broad applicability and significant disease-modifying impact. The program is currently in late preclinical development, with IND-enabling studies underway, paving a clear path toward clinical translation and vision preservation.

We are currently undertaking pre-clinical proof-of-concept research focused on retinal diseases, including Age Related Macular Degeneration and Glaucoma, before seeking partners to support the IND-enabling studies that precede the first-in-human clinical trials. Our immediate focus is to establish safety, target engagement, and biomarkers of early signals of neuroprotection in patients at risk of irreversible vision loss due to retinal cell death. Our long-term vision is to redefine how degenerative eye diseases are treated—shifting from managing late-stage consequences to preventing retinal cell death at its source. By targeting a shared upstream pathway, we aim to build a platform therapy utilizing an anti-Fas Ligand monoclonal antibody, with the potential to protect vision across multiple sight-loss conditions and ultimately change current standards of care in vision preservation.

EYVIVA is advancing a highly potent anti-Fas Ligand monoclonal antibody aimed at blocking apoptosis, which is a central upstream driver of retinal cell death and inflammation, particularly in conditions such as Age Related Macular Degeneration and Glaucoma. By targeting a unifying apoptotic pathway that is implicated in multiple retinal diseases, our therapeutic approach holds promise for broad applicability and significant disease-modifying impact. The program is currently in late preclinical development, with IND-enabling studies underway, paving a clear path toward clinical translation and vision preservation.

We are currently undertaking pre-clinical proof-of-concept research focused on retinal diseases, including Age Related Macular Degeneration and Glaucoma, before seeking partners to support the IND-enabling studies that precede the first-in-human clinical trials. Our immediate focus is to establish safety, target engagement, and biomarkers of early signals of neuroprotection in patients at risk of irreversible vision loss due to retinal cell death. Our long-term vision is to redefine how degenerative eye diseases are treated—shifting from managing late-stage consequences to preventing retinal cell death at its source. By targeting a shared upstream pathway, we aim to build a platform therapy utilizing an anti-Fas Ligand monoclonal antibody, with the potential to protect vision across multiple sight-loss conditions and ultimately change current standards of care in vision preservation.